A communication from the Executive Office of Health and Human Services (see item 4000-0300 of Section 2 of Chapter 140 of the Acts of 2024) submitting a report for total spending related to pharmaceutical utilization for fiscal year 2024; estimated spending related to pharmaceutical utilization for fiscal year 2025; and other spending impacts for fiscal years 2024 and 2025

This bill (HD 4952) is a procedural report submission required by Chapter 140 of the Acts of 2024. It provides the Executive Office of Health and Human Services with data on MassHealth’s pharmaceutical spending for fiscal year 2024 (totaling $2.74 billion before rebates) and estimates for fiscal year 2025 ($3.00 billion before rebates), including expected rebate collections ($1.78 billion) and federal funding impacts. The report details savings from negotiated drug rebates ($451 million annual value from 74 drugs), new drug additions to the MassHealth formulary (123 in FY2024, 100 in FY2025), and the program’s continued access to all FDA-approved drugs regardless of rebate agreements. This submission directly affects MassHealth’s budget transparency and accountability to the legislature.